TNF and neoplasm: These results are of particular importance to clinical studies, since TNF levels were not found to be raised in Phase I clinical trials of DMXAA but tumour blood flow shutdown at doses above 500 mg m−2 was clearly demonstrable (Rustin et al, 1998; Jameson et al, 2003).